Call Us: +91925476854
Explore clinically focused review articles designed to help physicians refine patient selection, understand risk factors, optimise SWL protocols, and apply evidence-based decision-making in daily stone management.
Background: Lower pole renal stones account for 30–40% of all renal calculi, making the lower pole the most common single calyceal location encountered in lithotripsy practice. Yet it presents extracorporeal shock wave lithotripsy (ESWL) with its most persistent anatomically defined challenge: the gravity-dependent position of the lower pole calyces means that even after successful stone fragmentation, resulting fragments must travel uphill against gravity to exit the collecting system — an obstacle absent for upper and middle calyceal stones. The distinction between fragmentation and fragment clearance is the conceptual cornerstone of lower pole ESWL outcomes, and explains why stone-free rates for this location are consistently lower than for anatomically equivalent stones in the renal pelvis. The lower pole infundibulopelvic angle (LIPA), infundibular length, and infundibular width collectively govern the geometry of fragment drainage and serve as the dominant predictors of ESWL success — in some series outweighing stone size as a prognostic variable.
Objectives: This article provides a comprehensive, evidence-based framework for clinical decision-making in lower pole stone management. It examines the anatomical basis of fragment clearance failure, the pre-procedural anatomical parameters that predict ESWL success, the comparative efficacy data for ESWL versus flexible ureterorenoscopy (FURS) and percutaneous nephrolithotomy (PCNL), the evidence for adjunct therapies to improve clearance rates — specifically Percussion, Diuresis, and Inversion (PDI) therapy — and a practical clinical protocol for patient selection, intraoperative technique, and post-procedure surveillance.
Methods: A structured narrative review was conducted incorporating the 2025 updated systematic review and meta-analysis of 24 RCTs published in European Urology (Pearle et al., doi: 10.1016/j.eururo.2025.01.028) — the most comprehensive synthesis available, including 16 new RCTs published since the 2015 Donaldson meta-analysis (7 RCTs, 691 patients, Eur Urol 2015); the Lee et al. network meta-analysis examining ESWL with adjuvant therapy as a distinct treatment arm (BJU Int 2015; PMID: 25381743); the anatomical series of Sampaio and Aragão establishing the IPA framework (J Urol 1992); multiple independent IPA outcome series including Madbouly et al. (Eur Urol 1999; 50 patients) and Sabnis et al. (Eur Urol 1999; 116 patients); the Pace et al. PDI randomized controlled trial (J Urol 2001; 112 patients); the El-Assmy intraoperative inversion RCT (PMC4397549); and the 2025 AUA and 2024 EAU urolithiasis guidelines.
Results: The 2025 updated meta-analysis confirms that PCNL achieves the highest stone-free rates (RR 1.42 vs ESWL; 95% CI 1.28–1.58), followed by FURS (RR 1.19 vs ESWL; 95% CI 1.05–1.35), with the authors describing the absolute differences as modest and ESWL retaining advantages of non-invasiveness, lower complication rates, no anaesthesia requirement, and substantially lower cost. LIPA is the dominant predictor of ESWL success across multiple independent series: Madbouly et al. demonstrated stone-free rates of 44% versus 86% based solely on LIPA below or above 90° (p < 0.001); Sabnis et al. found LIPA the only statistically significant predictor (p = 0.012) while stone size was not (p = 0.911) in 116 patients with 11–20 mm lower pole stones. Published ESWL stone-free rates range from 54–80% for stones ≤ 10 mm with favorable anatomy, falling to 21–44% with triple-unfavorable anatomy (LIPA < 70°, infundibular length > 50 mm, width < 4 mm) regardless of stone size. The Lee et al. network meta-analysis established that for stones < 10 mm, ESWL with adjuvant therapy achieves significantly better clearance than ESWL alone (RR 1.30; 95% CI 1.03–1.63), outperforms ureteroscopy alone, and carries fewer adverse events than PCNL — making it the optimal treatment combination for this size group. The Pace et al. RCT (112 patients) and Chiong et al. RCT confirmed PDI therapy as a Level 1 evidence-based adjunct for lower pole fragment clearance. The El-Assmy RCT demonstrated that intraoperative Trendelenburg positioning at 30 degrees combined with forced diuresis during ESWL — rather than post-procedural inversion — achieves significantly higher stone-free rates.
Conclusions: Lower pole ESWL outcomes are governed primarily by anatomy, not merely stone size. Pre-procedural measurement of LIPA, infundibular length, and infundibular width on CT or IVU is mandatory and should redirect patients with triple-unfavorable anatomy to FURS regardless of stone dimensions. For stones ≤ 10 mm with favorable anatomy, ESWL combined with PDI adjunct therapy — intraoperative forced diuresis (IV saline and furosemide), Trendelenburg positioning at 20–30 degrees, and mechanical percussion — represents the evidence-based optimal treatment. For stones 10–20 mm, FURS is preferred but ESWL remains valid with favorable anatomy. For stones > 20 mm, PCNL is the treatment of choice. Post-procedure alpha-blocker therapy (tamsulosin 0.4 mg daily) is mandated by the AUA 2025 Strong Recommendation. A maximum of three ESWL sessions should be applied before modality reassessment, and patients with two failed sessions should be redirected to FURS without further ESWL attempts.
The lower pole calyx is one of the most studied — and most debated — locations in the entire field of urinary stone surgery. Its significance derives not from its rarity but from its frequency: lower pole stones account for 30–40% of all renal calculi, making it by far the most common single calyceal location encountered in lithotripsy practice. Yet it is precisely this common location that poses ESWL’s most persistent and anatomically defined challenge: the gravity-dependent position of the lower pole calyces, which means that even when ESWL achieves excellent stone fragmentation, the resulting fragments must travel uphill against gravity to exit the collecting system — a physiological obstacle absent for upper and middle calyceal stones where fragments fall naturally toward the ureteropelvic junction.
The result is a paradox well-recognized in the literature: ESWL can fragment lower pole stones effectively, but clearance of those fragments is the problem. The distinction between fragmentation and clearance — terms that are sometimes conflated in clinical practice — is the conceptual cornerstone of understanding lower pole ESWL outcomes. It explains why stone-free rates for lower pole stones after ESWL are consistently lower than for equivalent-sized stones in the renal pelvis or upper calyces, and why the same ESWL session that achieves complete stone disintegration may still result in a patient who is not stone-free at 3 months because the fragments have not cleared.
This article examines the anatomy that drives this challenge, the evidence on patient selection and outcome prediction, the modality comparison data (ESWL vs FURS vs PCNL), the adjunct therapies that can improve fragment clearance, and the practical clinical protocol that my experience and the best available literature support. The most important paper in this field — the 2025 updated systematic review and meta-analysis covering 24 RCTs (16 new since 2015) published in European Urology, which is the most comprehensive and up-to-date synthesis available — frames the modality comparison throughout.
The lower pole of the kidney drains through a system of minor calyces that converge into one or more infundibula, which then join the renal pelvis. The critical anatomical variable for ESWL outcomes is the relationship of this infundibulum to the renal pelvis — specifically the angle at which the lower pole infundibulum meets the pelvis (the infundibulopelvic angle, IPA), the length of the infundibulum, and its diameter. These three anatomical parameters — collectively defining the geometry of the exit pathway through which post-ESWL fragments must travel — were first systematically characterized by Sampaio and Aragão at the State University of Rio de Janeiro in 1992, using three-dimensional endocasts of cadaveric collecting systems. Their work established the anatomical framework that has guided lower pole ESWL research for three decades.
The fundamental problem is directional: when a patient stands upright or lies supine, the lower pole calyces are gravity-dependent — they are the lowest point of the collecting system. Any stone fragment produced by ESWL within a lower calyx must travel against gravity to ascend into the infundibulum and reach the renal pelvis before it can exit via the ureter. CT and MRI studies have demonstrated that the lower calyces have an oblique axis of approximately 20–30 degrees relative to the horizontal — meaning that inversion of the patient by at least 30 degrees is required to create a gravity-favorable drainage angle. This is the physiological rationale for inversion therapy as an adjunct to lower pole ESWL.
Of all the anatomical parameters studied as predictors of lower pole ESWL success, the lower pole infundibulopelvic angle (LIPA) has emerged most consistently as the dominant factor. The LIPA is measured as the angle between the axis of the lower pole infundibulum and the axis of the renal pelvis on intravenous urography or CT. An obtuse LIPA (> 90°) creates a more open drainage geometry — fragments produced in the lower calyx face a less acute turn into the pelvis and are more likely to traverse it with gravity assistance or peristaltic force. An acute LIPA (< 90°) creates a sharp, constrictive turn that fragments must negotiate — a geometry analogous to a U-bend in plumbing, which traps debris regardless of fluid flow.
The clinical data supporting LIPA as the dominant predictor are remarkably consistent across multiple independent series:
| Study / Authors | Key Finding on LIPA | Stone-Free Rate Contrast |
|---|---|---|
| Sampaio et al. (J Endourol, 1997) — Endocast anatomical series | IPA < 90°, infundibular diameter < 4 mm: predicted clearance failure | 100% SFR in patients with IPA > 90° (Elbahnasy et al. follow-up data) |
| Madbouly et al. (Eur Urol, 1999) — 50 patients, Storz Modulith SL-20, stones 10–20 mm | IPA 90°: 86% stone-free. | 44% vs 86% — nearly twofold difference driven solely by angle |
| Karger / European Urology series — 116 patients, stones 11–20 mm | IPA was the ONLY statistically significant predictor (p = 0.012). Stone size did not predict SFR (p = 0.911). | Obtuse IPA, large infundibular diameter, no calyceal distortion: associated with stone-free status |
| European Urology Sampaio series — 205 renal units, stones ≤ 25 mm | LIPA was most significant factor (p = 0.00001). Infundibular length also significant (p = 0.039). LIP-A ≥ 70°, infundibular length < 50 mm: preferable for favorable outcome. | Average 1.6 sessions, 3,277 shockwaves per session |
| Journal of Urology series (PMID: 12352389) — 63 patients, stones ≤ 2 cm | Caliceal pelvic height, infundibular diameter, length, length-to-diameter ratio, and number of minor calices all differed significantly between stone-free and non-stone-free patients. | Overall clearance rate 54%; ESWL advocated if ≥1 favorable factor: >60% chance of success |
The clinical implication of this convergent evidence is direct and actionable: measurement of the LIPA on pre-procedure IVU or CT should be a standard component of pre-ESWL assessment for lower pole stones. A patient with a LIPA < 70°, infundibular length > 50 mm, and infundibular diameter < 4 mm — the triple-unfavorable anatomy — has a predicted stone-free rate after ESWL in the range of 21–44% regardless of stone size within the ≤ 2 cm range. This patient is much better served by FURS or mini-PCNL at the outset, rather than by multiple ESWL sessions that deliver renal parenchymal trauma without achieving stone-free status.
A further anatomical nuance that affects ESWL planning is that the lower pole is not a uniform single calyx: the lower pole moiety typically drains through one to four minor calyces that converge into the lower infundibulum. Stones in a single lower calyx with a wide-mouthed infundibulum and favorable IPA respond well to ESWL. Stones distributed across multiple lower calices (a lower pole stone burden) present a fundamentally different fragmentation and clearance challenge — even if individual stone fragments are small, the multiple-calyx distribution means fragments must drain from multiple locations simultaneously, each with its own drainage geometry. For a patient with a distributed lower pole stone burden > 15 mm total, FURS — which allows direct endoscopic visualization and treatment of individual minor calices — is substantially better suited than ESWL.
The most comprehensive and current evidence synthesis is the Updated Systematic Review and Meta-analysis of ESWL, Flexible Ureterorenoscopy (FURS), and PCNL for Lower Pole Renal Stones, published in European Urology in March 2025, incorporating 24 RCTs — including 16 new RCTs published since the original 2015 review. This represents the current gold standard for evidence-based decision-making for lower pole stones. The key findings are:
| Comparison | Stone-Free Rate Result | Other Key Outcomes |
|---|---|---|
| FURS vs ESWL | FURS superior: RR 1.19 (95% CI 1.05–1.35). Absolute difference remains modest. | ESWL: fewer complications. FURS: more unplanned procedures and retreatments. QoL: no difference. Costs: ESWL cheaper (UK and China data). |
| PCNL vs ESWL | PCNL superior: RR 1.42 (95% CI 1.28–1.58). Unplanned procedures and retreatments fewer for PCNL. | ESWL: fewer complications. PCNL: higher invasiveness, longer hospital stay. |
| PCNL vs FURS | PCNL marginally superior: RR 1.07 (95% CI 1.01–1.12). Differences in retreatments and complications unclear. | Conflicting evidence on health status and return to normal activities. |
The authors’ overall conclusion is measured and important: “PCNL achieves the highest stone-free rates, followed by FURS, with ESWL yielding the lowest rates. However, the absolute differences in efficacy appear modest.” The word “modest” is not exculpatory — it reflects that a RR of 1.19 for FURS over ESWL means approximately a 15–20% absolute increase in stone-free rate in favour of FURS, which is clinically meaningful for the individual patient but should be weighed against ESWL’s advantages of non-invasiveness, no anaesthesia requirement, lower complication rate, outpatient delivery, and substantially lower cost. The review also explicitly acknowledges that despite inclusion of 16 new RCTs, the certainty of evidence remains only moderate, reflecting ongoing methodological heterogeneity across trials.
The original Donaldson, Lardas, Scrimgeour et al. systematic review in European Urology (2015) — the predecessor to the 2025 update — established the evidence base with 691 patients from 12 articles across 7 RCTs. The key findings were: stone-free rates were highest after PCNL; RIRS (FURS) offered higher stone-free rates than ESWL; ESWL was the least invasive, with shortest convalescence and highest patient acceptability. The accompanying commentary by Kim BS in Annals of Translational Medicine (2016) crystallized the clinical guidance: “There is no doubt that endoscopic procedures can achieve better stone-free outcomes for lower-pole stones with a diameter exceeding 10 mm as compared to ESWL.” For stones ≤ 10 mm, the picture is more nuanced.
The network meta-analysis by Lee, Chaiyakunapruk, Chong, and Liong (BJU International, 2015; PMID: 25381743) is unique in the literature because it specifically examined ESWL with adjuvant therapy (SWL+ADJ) as a distinct treatment arm, alongside PCNL, URS, and ESWL alone. The network included all comparative treatment procedures for lower pole renal calculi. For stones < 10 mm, the results were striking: SWL with adjuvant therapy achieved significantly better stone clearance (RR 1.30, 95% CI 1.03–1.63) than SWL alone, while also outperforming URS alone (RR 1.23) and having a lower risk of adverse events than PCNL (RR 2.19). The conclusion: for stones < 10 mm in the lower pole, ESWL with adjuvant therapy (inversion, diuresis, mechanical percussion) is the optimal treatment combination — more effective than ESWL alone and with fewer adverse events than PCNL.”
This finding is of direct practical importance: it means the appropriate question for small lower pole stones is not simply “ESWL or not?” but “ESWL with adjunct or not?” — and the evidence strongly supports the augmented protocol.
Published stone-free rates for lower pole stones after ESWL span a wide range, reflecting heterogeneity in stone size, anatomy, lithotripter technology, and adjunct use. The following values are well-established in the peer-reviewed literature:
The wide SFR range for the 10–20 mm size group reflects the dominant role of anatomy over size in this range — a finding consistently reported across multiple series and most compellingly by the Karger/European Urology series, where stone size did not predict SFR (p = 0.911) but anatomy did (p = 0.012) in 116 patients with lower pole stones measuring 11–20 mm.
The concept of adjunct physical manoeuvres to improve lower pole fragment clearance after ESWL was first formally evaluated by Brownlee, Foster, Griffith, and Carlton in Journal of Urology (1990), who reported the first controlled evaluation of inversion therapy with parenteral hydration and percussion — demonstrating both safety and efficacy in relocating lower pole fragments to more favorable calyceal positions. The technique has since been refined into the standard Percussion, Diuresis, and Inversion (PDI) protocol, which is the most widely studied adjunct in lower pole ESWL.
The definitive clinical evidence comes from the prospective randomized controlled trial by Pace, Tariq, Dyer, Weir, and Honey (Journal of Urology, 2001), which randomized 112 patients with lower pole stones to SWL alone or SWL with PDI therapy. The PDI protocol comprised: mechanical percussion of the renal area, diuresis, and controlled inversion therapy. The result: PDI therapy significantly improved lower pole stone clearance, leading the authors to conclude that “PDI therapy is a valuable adjunct in assisting passage of lower pole renal stone fragments after SWL therapy.” The study established PDI as a Level 1 evidence-based adjunct for lower pole ESWL.
The Singapore randomized controlled trial by Chiong, Tay, Li, Shen, Kamaraj, and Esuvaranathan (Urology, 2005) further confirmed this, showing that mechanical percussion combined with diuresis and inversion significantly improved lower pole stone clearance versus ESWL alone. The clinical experience from the Sindh Institute of Urology and Transplantation (SIUT) series of 215 patients (January–July 2018) using IV hydration (1 litre normal saline), furosemide 40 mg IV 5 minutes before ESWL, and 20-degree table inversion confirmed effectiveness of the adjunct protocol in a high-volume real-world setting.
The PDI protocol as described and validated in published series consists of three simultaneous components:
A refinement of the PDI concept is intraoperative table inversion during the ESWL session itself — delivering shock waves while the patient is in the Trendelenburg position, so that fragments are produced and immediately exit the lower calyx under gravity-favorable conditions, rather than being produced in the dependent position and then inverted afterward. The randomized controlled study by El-Assmy et al. (Dornier Lithotripter SII, Dornier MedTech Wessling, Germany) evaluated two groups: SWL with simultaneous Trendelenburg positioning at 30 degrees + IV hydration (1000 mL NS) + IV furosemide 20 mg (study group) versus standard SWL (control group). The study group achieved significantly higher stone-free rates (p < 0.05) with the combination protocol, confirming the benefit of intraoperative rather than post-procedural inversion.
The 2025 AUA Guideline (Statement 43, Strong Recommendation) mandates prescribing alpha-adrenergic blockers after ESWL to improve stone-free rates and reduce post-operative pain. For lower pole stones specifically, the alpha-blocker effect on the infundibular smooth muscle — relaxing it and potentially widening the functional infundibular diameter — may be particularly relevant. While the direct evidence for alpha-blockers specifically in lower pole ESWL is less robust than for ureteric stones, the guideline’s Strong Recommendation applies to all post-ESWL patients and should be standard practice in lower pole cases. Tamsulosin 0.4 mg once daily is the standard regimen, continued until stone-free status is confirmed at follow-up imaging.
As established in the lower ureteric stone article in this series, the 2025 AUA Guideline Statement 41 (Clinical Principle) explicitly advises against routine pre-ESWL ureteral stenting to improve stone-free rates. For lower pole stones specifically, a DJ stent does not address the fundamental problem — gravity-dependent calyceal drainage — and may reduce the ureteric peristalsis that drives fragment expulsion. Routine stenting before lower pole ESWL is not supported by evidence and not recommended
The current international guidelines — EAU 2024 and AUA 2025 — both use stone size as the primary modality selection criterion for lower pole stones, while explicitly acknowledging that anatomical factors (IPA, infundibular length, stone density) modify this size-based framework. The evidence-based thresholds are:
| Stone Size | Recommended Modality | Evidence Basis |
|---|---|---|
| ≤ 10 mm | ESWL first-line — with adjunct PDI therapy strongly recommended. FURS is an alternative if anatomy is unfavorable (IPA < 70°). | Lee et al. network meta-analysis (BJU Int 2015): SWL+ADJ is optimal for <10 mm with best safety profile. EAU 2024 guideline. |
| 10–20 mm | FURS preferred over ESWL based on 2025 updated meta-analysis (RR 1.19). ESWL remains a valid option if anatomy is favorable (IPA ≥ 90°, wide infundibulum). | Donaldson Eur Urol 2015; 2025 updated meta-analysis; Kim commentary Ann Transl Med 2016: 'No doubt endoscopic procedures achieve better SFR for >10 mm'. |
| > 20 mm | Mini-PCNL or standard PCNL — highest SFR (RR 1.42 vs ESWL). ESWL SFR < 25%; multiple sessions required; residual fragment rate high. | 2025 updated meta-analysis; AUA 2025; EAU 2024: PCNL recommended for >20 mm lower pole stones. |
| Any size — unfavorable anatomy | FURS regardless of size — anatomy overrides size as predictor. IPA < 70° with narrow long infundibulum: ESWL SFR 21–44% regardless of stone size. | Karger Eur Urol series (stone size NOT predictor, p=0.911; anatomy IS, p=0.012); Madbouly 44% vs 86% based on IPA alone. |
The current international guidelines — EAU 2024 and AUA 2025 — both use stone size as the primary modality selection criterion for lower pole stones, while explicitly acknowledging that anatomical factors (IPA, infundibular length, stone density) modify this size-based framework. The evidence-based thresholds are:
| Assessment | Requirement | Rationale |
|---|---|---|
| NCCT KUB (non-contrast CT) | Document: stone size (maximum diameter + total stone burden), Hounsfield units (HU), number of stones, stone location within lower pole, skin-to-stone distance (SSD). | HU predicts fragmentation; SSD predicts energy delivery; stone burden guides session planning |
| Lower pole anatomy measurement | Measure LIPA, infundibular length (IL), and infundibular width (IW) on CT coronal reconstruction or IVU. Record all three values. | LIPA < 70°: redirect to FURS regardless of stone size. Anatomy is the dominant predictor. |
| KUB X-ray | Confirm radiopacity. Radiolucent stone on KUB requires IVU or retrograde contrast for targeting confirmation. | Radiolucent lower pole stone (uric acid): consider alkalinization first; if ESWL: ultrasound or contrast guidance essential |
| Urine culture | Mandatory before ESWL. Treat any bacteriuria before proceeding. | Lower pole fragments remaining post-ESWL act as a nidus for infection; sterile urine before treatment is non-negotiable |
| Renal function | Serum creatinine / eGFR. Document baseline. | Fragmentation produces renal parenchymal stress; impaired function requires more conservative session planning |
| Stone composition history | Review any prior stone analysis. Cystine/brushite: redirect to FURS immediately. | Stone composition independent of HU may override other favorable factors |
| BMI and SSD | SSD > 10–12 cm: counsel re reduced SFR. BMI > 35: consider FURS as primary option. | Body habitus independently predicts ESWL outcome |
| Patient counselling | Counsel explicitly re: lower pole SFR (37–80% depending on anatomy/size); PDI adjunct therapy commitment; likely need for ≥ 2 sessions; alpha-blocker post-procedure. | Informed consent for lower pole ESWL must be more detailed than for renal pelvis stones — realistic expectations are essential |
| Parameter | Lower Pole Specific Protocol |
|---|---|
| PDI adjunct preparation | Begin IV hydration (500–1000 mL normal saline) 30 minutes before ESWL. Administer IV furosemide 20–40 mg approximately 10 minutes before initiating shock waves. Aim for urine output of 200–400 mL/hour during treatment. |
| Table positioning | Position patient in Trendelenburg (head-down) at 20–30 degrees for the duration of treatment if lithotripter table permits. If intraoperative inversion not possible: plan post-procedure inversion + percussion protocol immediately after session. |
| Targeting modality | Fluoroscopy for radiopaque stones (standard). Ultrasound or IVU contrast guidance for radiolucent stones. Confirm lower pole calyceal stone location pre-treatment. |
| Shock wave rate | 60/min — AUA 2025 Guideline (Moderate Recommendation). Do not use 120/min default rate. |
| Energy ramping | Mandatory stepwise escalation: begin at lowest effective voltage, increase incrementally. Do not start at maximum energy setting. |
| Total shock waves | 2,000–3,000 per session. For anatomy-unfavorable patients already in ESWL (clinical decision made): limit total shocks and assess fragmentation actively at 1,500-shock intervals. |
| Fragmentation monitoring | Confirm visual evidence of stone disintegration on fluoroscopy during session. No fragmentation visible at 2,000 shocks with maximum appropriate energy: document and plan modality reassessment. |
| Post-procedure percussion | If intraoperative inversion was used: continue inversion position for 10 minutes post-procedure. Administer 10 minutes of mechanical flank percussion in the inverted position before return to supine. |
| Contraindication Type | Condition |
|---|---|
| Absolute | Pregnancy |
| Absolute | Uncorrected coagulopathy (INR > 1.5, platelets < 80,000/μL) |
| Absolute | Active urinary tract infection — treat and confirm sterile urine before proceeding |
| Absolute | Calyceal diverticulum stone — fragments cannot exit regardless of ESWL success; FURS with diverticulotomy required |
| Absolute | Cystine stone confirmed on prior analysis — ESWL-resistant; FURS with holmium laser |
| Relative | Stone > 10 mm with unfavorable anatomy (IPA < 70°) — redirect to FURS; expected ESWL SFR 21–44% |
| Relative | Stone > 20 mm — PCNL preferred; ESWL SFR < 25% with high retreatment burden |
| Relative | Stone density (HU) > 1000 — poor fragmentation expected regardless of anatomy; FURS preferred |
| Relative | BMI > 35 with SSD > 12 cm — acoustic attenuation severely reduces effective shock wave delivery |
| Relative | Multiple lower caliceal stones (distributed stone burden) — FURS addresses each calyx; ESWL cannot |
| Relative | Prior 2 failed ESWL sessions for same stone — switch modality; do not continue ESWL |
| Not a contraindication | Mild hydronephrosis — does not preclude ESWL; may facilitate fragment drainage from lower pole |
| Not a contraindication | Solitary kidney — ESWL is feasible with conservative protocol; rate reduction and total shock wave limits mandatory; careful monitoring |
